RXRX: AI-driven drug discovery engine delivers first-in-class assets and strong partnership milestones
The conference highlighted a strategic transformation to an AI-driven, end-to-end drug discovery engine, with significant cost reductions and repeatable productivity. Key clinical assets like REC-4881 and REC-1245 are advancing, supported by exclusive partnerships and robust milestone achievements…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.